Parallel Advisors’s Seres Therapeutics MCRB Stock Holding History

Parallel Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1	Closed	-$77	–	3439
2023 Q2	$77	Sell	1 -1	-50%	-$109	﹤0.01%	3300
2023 Q1	$221	Buy	+2	New	+$216	﹤0.01%	3265
2017 Q1	–	Sell	-15	Closed	-$3K	–	2043
2016 Q4	$3K	Buy	+15	New	+$3.27K	﹤0.01%	1537

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Parallel Advisors's MCRB Position: Q3 2023 in Review

Parallel Advisors sold out of Seres Therapeutics (MCRB) in Q3 2023, closing a stake of 1 share — an estimated $77 sold.

Parallel Advisors first reported a position in MCRB in Q4 2016 and held it in 3 quarters. The position peaked at $3K in Q4 2016. 134 funds tracked by Wall St. Rank hold MCRB as of Q3 2023.

Parallel Advisors reported no remaining Seres Therapeutics position as of Q3 2023 after selling out during the quarter.
Parallel Advisors sold 1 Seres Therapeutics share in Q3 2023, an estimated $77.
Parallel Advisors first reported a position in Seres Therapeutics in Q4 2016 and held it in 3 quarters.
Parallel Advisors's Seres Therapeutics position peaked at $3K in Q4 2016.
134 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2023.

Based on Parallel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.